Xlumena, a Mountain View, California-based provider of innovative technology for the interventional endoscopist and endoscopic surgeon, has closed a $7m Series B financing.
The round was led by new investor Aperture Venture Partners, LLC, with participation from Western Technology Investment and existing backers Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures.
The company has raised raisedĀ $19mĀ from to date.
In conjunction with the financing,Ā Eric SillmanĀ of Aperture Venture Partners andĀ Avi Kometz, MD of Ascent Biomedical Ventures, will join Xlumena’s Board of Directors.
As stated by Michael Allen, President and CEO of Xlumena, the financing will support the company’s market expansion in the US andĀ Europe.
Founded in 2008 byĀ Kenneth Binmoeller, MD, andĀ Allen, Xlumena has a number of advanced therapeutic devices in various stages of development, including the NAVIXā¢ Access Device (FDA-cleared) and the AXIOSā¢ Stent and Delivery System (CE marked).
FinSMEs
29/04/2011